Trial Outcomes & Findings for A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) (NCT NCT00779584)

Last Updated: 2018-08-27

Results Overview

During Cycle 0, a DLT was defined as: CTCAE v 3.0 Grade 3 neutropenia or thrombocytopenia lasting ≥3 days; any CTCAE v 3.0 Grade 4 neutropenia or thrombocytopenia; neutropenic fever; any CTCAE v. 3.0 ≥ Grade 3 QT interval corrected by Fridericia (QTcF) prolongation of any duration; any other CTCAE v 3.0 Grade 3 or higher nonhematologic toxicity; or Grade 3 elevation of transaminases that resolved prior to administration of next dose(s) of study drug(s); delay in Cycle 1 Day 1 beyond 3 weeks due to continuing toxicity. During Cycle 1, a DLT was defined as: CTCAE v 3.0 Grade 4 neutropenia that persists for ≥7 days; neutropenic fever; CTCAE v 3.0 Grade 4 thrombocytopenia; CTCAE v 3.0 ≥ Grade 3 thrombocytopenia with bleeding; any CTCAE v 3.0 QTc ≥ Grade 3 QTcF prolongation of any duration; any other CTCAE v 3.0 Grade 3 or higher nonhematologic toxicity; or Grade 3 elevation of transaminases that resolved prior to administration of next dose(s) of study drug(s).

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

45 participants

Primary outcome timeframe

Through Cycle 0 and Cycle 1 (Up to 42 days)

Results posted on

2018-08-27

Participant Flow

Participant milestones

Participant milestones
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 10 mg/m\^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Overall Study STARTED	3	3	7	6	7	6	8	3	2
Overall Study Treated	3	3	7	6	7	4	8	3	2
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	3	7	6	7	6	8	3	2

Reasons for withdrawal

Reasons for withdrawal
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 10 mg/m\^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Overall Study Protocol Violation	0	0	0	0	0	1	0	0	0
Overall Study Withdrawal by Subject	1	1	2	0	0	2	1	0	0
Overall Study Lost to Follow-up	0	0	0	0	1	0	0	0	0
Overall Study Progression of Disease	0	1	2	6	5	1	4	2	1
Overall Study Adverse Event	1	0	2	0	0	0	2	1	1
Overall Study Symptomatic Deterioration	1	1	1	0	0	1	1	0	0
Overall Study Ongoing in Study	0	0	0	0	1	1	0	0	0

Baseline Characteristics

A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	Total n=45 Participants Total of all reporting groups
Age, Continuous	54.3 Years STANDARD_DEVIATION 16.0 • n=5 Participants	54.3 Years STANDARD_DEVIATION 8.6 • n=7 Participants	64.0 Years STANDARD_DEVIATION 16.1 • n=5 Participants	55.5 Years STANDARD_DEVIATION 5.0 • n=4 Participants	51.1 Years STANDARD_DEVIATION 5.7 • n=21 Participants	59.0 Years STANDARD_DEVIATION 13.4 • n=8 Participants	59.9 Years STANDARD_DEVIATION 9.1 • n=8 Participants	69.3 Years STANDARD_DEVIATION 5.5 • n=24 Participants	69.0 Years STANDARD_DEVIATION 8.5 • n=42 Participants	58.8 Years STANDARD_DEVIATION 11.2 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants	2 Participants n=8 Participants	3 Participants n=8 Participants	1 Participants n=24 Participants	2 Participants n=42 Participants	18 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	3 Participants n=7 Participants	5 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	4 Participants n=8 Participants	5 Participants n=8 Participants	2 Participants n=24 Participants	0 Participants n=42 Participants	27 Participants n=42 Participants

PRIMARY outcome

Timeframe: Through Cycle 0 and Cycle 1 (Up to 42 days)

Population: The population consisted of all participants who were evaluable for DLT assessment (i.e., completed Cycle 0 and Cycle 1).

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=6 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 0 and Cycle 1 Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v 3.0)	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	1 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment)

Population: The population consisted of all participants who received at least one dose of MK-8776.

An AE was defined as any untoward medical occurrence in a participant administered study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could have been any unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to study treatment. The number of participants who experienced an AE is presented.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Number of Participants Who Experienced an Adverse Event (AE)	3 Participants	3 Participants	7 Participants	6 Participants	7 Participants	4 Participants	8 Participants	3 Participants	2 Participants

PRIMARY outcome

Timeframe: Up to approximatey 66 weeks

Population: The population consisted of all participants who received at least one dose of MK-8776.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Number of Participants Who Discontinued Study Treatment Due to an AE	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: At end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion

Population: The population consisted of all participants who received at least two cycles of study treatment.

The Cmax of MK-8776 was assessed in Cycle 0 and in Cycle 1. On Day 1 of Cycle 0 and Cycle 1, plasma samples were obtained from all participants before infusion, at end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
MK-8776 Maximum Plasma Concentration (Cmax) Cycle 0 (n=3, 3, 7, 6, 7, 4, 8, 3, 2)	414 ng/mL Standard Deviation 257	1010 ng/mL Standard Deviation 197	1220 ng/mL Standard Deviation 366	4970 ng/mL Standard Deviation 1500	5270 ng/mL Standard Deviation 3730	2960 ng/mL Standard Deviation 1290	6210 ng/mL Standard Deviation 2160	6220 ng/mL Standard Deviation 2550	4860 ng/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when the number of participants analyzed (n) ≥ 3.
MK-8776 Maximum Plasma Concentration (Cmax) Cycle 1 (n=3, 3, 7, 5, 6, 4, 6, 1, 2)	445 ng/mL Standard Deviation 249	1650 ng/mL Standard Deviation 1520	962 ng/mL Standard Deviation 454	3700 ng/mL Standard Deviation 1930	4710 ng/mL Standard Deviation 2310	3610 ng/mL Standard Deviation 2290	4690 ng/mL Standard Deviation 2610	4940 ng/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.	3700 ng/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.

SECONDARY outcome

Timeframe: At end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion

Population: The population consisted of all participants who received at least two cycles of study treatment.

AUC0-last was assessed in Cycle 0 and in Cycle 1. On Day 1 of Cycle 0 and Cycle 1, plasma samples were obtained from all participants before infusion, at end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion. AUC0-last was calculated by the linear trapezoidal method.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
MK-8776 Area Under the Curve of the Plasma Concentration Versus Time From Time Zero to the Time of the Last Analytically Quantifiable Concentration (AUC0-last) Cycle 1 (n=3, 3, 7, 5, 6, 4, 6, 1, 2)	539 ng*hr/mL Standard Deviation 307	1570 ng*hr/mL Standard Deviation 423	1900 ng*hr/mL Standard Deviation 859	4540 ng*hr/mL Standard Deviation 1660	10300 ng*hr/mL Standard Deviation 6370	4660 ng*hr/mL Standard Deviation 815	6900 ng*hr/mL Standard Deviation 3120	13000 ng*hr/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.	16900 ng*hr/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.
MK-8776 Area Under the Curve of the Plasma Concentration Versus Time From Time Zero to the Time of the Last Analytically Quantifiable Concentration (AUC0-last) Cycle 0 (n=3, 3, 7, 6, 7, 4, 8, 3, 2)	565 ng*hr/mL Standard Deviation 171	1400 ng*hr/mL Standard Deviation 448	2250 ng*hr/mL Standard Deviation 948	5060 ng*hr/mL Standard Deviation 1920	9050 ng*hr/mL Standard Deviation 5500	4040 ng*hr/mL Standard Deviation 1010	9240 ng*hr/mL Standard Deviation 5740	18500 ng*hr/mL Standard Deviation 8000	8440 ng*hr/mL Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.

SECONDARY outcome

Timeframe: At end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion

Population: The population consisted of all participants who received at least two cycles of study treatment.

The time of Cmax of MK-8776 was assessed in Cycle 0 and in Cycle 1. On Day 1 of Cycle 0 and Cycle 1, plasma samples were obtained from all participants before infusion, at end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=2 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Time of MK-8776 Cmax (Tmax) Cycle 0 (n=3, 3, 7, 6, 7, 4, 8, 3, 2)	0.27 hr Standard Deviation 0.03	0.26 hr Standard Deviation 0.01	0.29 hr Standard Deviation 0.06	0.24 hr Standard Deviation 0.03	0.30 hr Standard Deviation 0.08	0.26 hr Standard Deviation 0.05	0.23 hr Standard Deviation 0.02	0.48 hr Standard Deviation 0.02	0.49 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.
Time of MK-8776 Cmax (Tmax) Cycle 1 (n=3, 3, 7, 5, 6, 4, 6, 1, 2)	0.26 hr Standard Deviation 0.01	0.27 hr Standard Deviation 0.02	0.35 hr Standard Deviation 0.13	0.25 hr Standard Deviation 0.06	0.28 hr Standard Deviation 0.06	0.26 hr Standard Deviation 0.03	0.23 hr Standard Deviation 0.01	0.50 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.	0.57 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.

SECONDARY outcome

Timeframe: At end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion

Population: The population consisted of all participants who received at least two cycles of study treatment.

The t1/2 of MK-8776 was assessed in Cycle 0 and in Cycle 1. On Day 1 of Cycle 0 and Cycle 1, plasma samples were obtained from all participants before infusion, at end of infusion of MK-8776 (Cycle 0) or gemcitabine (Cycle 1), and at 0.25, 1, 3, 6, 8, 24 and 48 hours after completion of MK-8776 infusion.

Outcome measures

Outcome measures
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 Participants Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 Participants Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 Participants Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg+Gemcitabine 1000mg/m^2 n=3 Participants Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
MK-8776 Terminal Phase Half-Life (t1/2) Cycle 0 (n=3, 3, 7, 6, 7, 4, 8, 3, 2)	6.29 hr Standard Deviation 1.97	9.33 hr Standard Deviation 5.09	8.45 hr Standard Deviation 2.95	7.44 hr Standard Deviation 0.435	5.94 hr Standard Deviation 1.62	8.13 hr Standard Deviation 1.30	7.14 hr Standard Deviation 1.90	9.46 hr Standard Deviation 2.11	6.30 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.
MK-8776 Terminal Phase Half-Life (t1/2) Cycle 1 (n=3, 3, 6, 6, 7, 4, 7, 1, 2)	6.24 hr Standard Deviation 2.03	8.57 hr Standard Deviation 4.54	8.23 hr Standard Deviation 1.71	9.01 hr Standard Deviation 2.51	7.29 hr Standard Deviation 1.26	7.87 hr Standard Deviation 2.11	7.98 hr Standard Deviation 1.21	7.59 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.	9.89 hr Standard Deviation NA By Sponsor convention, standard deviations are only calculated when n ≥ 3.

Adverse Events

MK-8776 10mg/m^2+Gemcitabine 800mg/m^2

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

MK-8776 20mg/m^2+Gemcitabine 800mg/m^2

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

MK-8776 40mg/m^2+Gemcitabine 800mg/m^2

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

MK-8776 80mg/m^2+Gemcitabine 800mg/m^2

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

MK-8776 112mg/m^2+Gemcitabine 800mg/m^2

Serious events: 2 serious events

Other events: 7 other events

Deaths: 0 deaths

MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2

Serious events: 3 serious events

Other events: 4 other events

Deaths: 0 deaths

MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2

Serious events: 4 serious events

Other events: 8 other events

Deaths: 0 deaths

MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

MK-8776 200mg Flat Dose+Gemcitabine 1000mg/m^2

Serious events: 2 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 participants at risk Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 participants at risk Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 participants at risk Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 participants at risk Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 participants at risk Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 participants at risk Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 participants at risk Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 participants at risk Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg Flat Dose+Gemcitabine 1000mg/m^2 n=2 participants at risk Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Cardiac disorders ATRIAL FIBRILLATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Cardiac disorders CARDIOMYOPATHY	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Cardiac disorders SUPRAVENTRICULAR TACHYCARDIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ABDOMINAL PAIN	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders CONSTIPATION	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders DUODENAL OBSTRUCTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ENTEROCUTANEOUS FISTULA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders VOMITING	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CHEST PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders PYREXIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Hepatobiliary disorders CHOLANGITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Hepatobiliary disorders HYPERBILIRUBINAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations ABDOMINAL ABSCESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations MASTOIDITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations PNEUMOCYSTIS JIROVECI PNEUMONIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations PNEUMONIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications HIP FRACTURE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations ELECTROCARDIOGRAM QT PROLONGED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders DEHYDRATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT MELANOMA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders CONVULSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders NEUROLOGICAL SYMPTOM	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders SYNCOPE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders ANXIETY	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders DYSPNOEA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.

Other adverse events

Other adverse events
Measure	MK-8776 10mg/m^2+Gemcitabine 800mg/m^2 n=3 participants at risk Participants received MK-8776 10 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 20mg/m^2+Gemcitabine 800mg/m^2 n=3 participants at risk Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 40mg/m^2+Gemcitabine 800mg/m^2 n=7 participants at risk Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 800mg/m^2 n=6 participants at risk Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 800mg/m^2 n=7 participants at risk Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2 n=4 participants at risk Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2 n=8 participants at risk Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2 n=3 participants at risk Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.	MK-8776 200mg Flat Dose+Gemcitabine 1000mg/m^2 n=2 participants at risk Participants received MK-8776 200 mg given as a flat dose monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
Hepatobiliary disorders BILE DUCT OBSTRUCTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Hepatobiliary disorders BILIARY DILATATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders DIABETES MELLITUS INADEQUATE CONTROL	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPERCHOLESTEROLAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPERKALAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOALBUMINAEMIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOCALCAEMIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOGLYCAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOMAGNESAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders HYPOPHOSPHATAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders ARTHRALGIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders BACK PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 2/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders FIBROMYALGIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders FLANK PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders GROIN PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders LIMB DISCOMFORT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCLE TIGHTNESS	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCULAR WEAKNESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL CHEST PAIN	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL DISCOMFORT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Blood and lymphatic system disorders ANAEMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Blood and lymphatic system disorders LEUKOPENIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Blood and lymphatic system disorders LYMPHOPENIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Blood and lymphatic system disorders NEUTROPENIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 2/4 • Number of events 7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 4/8 • Number of events 13 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Blood and lymphatic system disorders THROMBOCYTOPENIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	42.9% 3/7 • Number of events 6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 4/8 • Number of events 6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Cardiac disorders SINUS TACHYCARDIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Ear and labyrinth disorders EUSTACHIAN TUBE OBSTRUCTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Ear and labyrinth disorders MIDDLE EAR EFFUSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Eye disorders EYE IRRITATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Eye disorders EYE PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Eye disorders VISUAL IMPAIRMENT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ABDOMINAL DISTENSION	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ABDOMINAL PAIN	66.7% 2/3 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 2/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders ASCITES	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders COLITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders CONSTIPATION	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 3/6 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	37.5% 3/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders DENTAL DISCOMFORT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders DIARRHOEA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders DRY MOUTH	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders DYSPEPSIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders FAECAL INCONTINENCE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders GASTRITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders GINGIVAL PAIN	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders HAEMATOCHEZIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders HAEMORRHOIDAL HAEMORRHAGE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders NAUSEA	100.0% 3/3 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 3/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	57.1% 4/7 • Number of events 6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	75.0% 3/4 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	100.0% 3/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders SALIVARY GLAND ENLARGEMENT	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders SENSITIVITY OF TEETH	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders STOMATITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Gastrointestinal disorders VOMITING	66.7% 2/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	57.1% 4/7 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders ASTHENIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CATHETER SITE HAEMATOMA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CATHETER SITE PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CHEST DISCOMFORT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CHEST PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders CHILLS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders EARLY SATIETY	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders FATIGUE	66.7% 2/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	66.7% 2/3 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	71.4% 5/7 • Number of events 6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	83.3% 5/6 • Number of events 7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	85.7% 6/7 • Number of events 9 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	100.0% 4/4 • Number of events 10 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 4/8 • Number of events 6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders GENERALISED OEDEMA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations EYE INFECTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders INFLUENZA LIKE ILLNESS	33.3% 1/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders INFUSION SITE PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders MUCOSAL INFLAMMATION	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications TRANSFUSION REACTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders NON-CARDIAC CHEST PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	66.7% 2/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders OEDEMA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders OEDEMA PERIPHERAL	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	57.1% 4/7 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 3/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
General disorders PYREXIA	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Hepatobiliary disorders HEPATIC PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Hepatobiliary disorders HYPERBILIRUBINAEMIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations CANDIDIASIS	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations CATHETER SITE INFECTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations CELLULITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations ALANINE AMINOTRANSFERASE INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations ASPARTATE AMINOTRANSFERASE INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations HERPES ZOSTER	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations NASOPHARYNGITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations ORAL CANDIDIASIS	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations ORAL HERPES	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations RESPIRATORY TRACT INFECTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations SINUSITIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations TINEA MANUUM	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Infections and infestations URINARY TRACT INFECTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications CONTUSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications EXCORIATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications MUSCLE STRAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Injury, poisoning and procedural complications PROCEDURAL PAIN	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders HEADACHE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations BLOOD CREATININE INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders NASAL DRYNESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations BLOOD PRESSURE INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations BREATH SOUNDS ABNORMAL	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations ELECTROCARDIOGRAM QT PROLONGED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 25 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	100.0% 3/3 • Number of events 5 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations HAEMOGLOBIN DECREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations INTERNATIONAL NORMALISED RATIO INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations NEUTROPHIL COUNT DECREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations PLATELET COUNT DECREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations WEIGHT DECREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations WEIGHT INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Investigations WHITE BLOOD CELL COUNT INCREASED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders DECREASED APPETITE	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	66.7% 2/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	42.9% 3/7 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 3/6 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	100.0% 4/4 • Number of events 4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Metabolism and nutrition disorders DEHYDRATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders HYPOGEUSIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL STIFFNESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders MYALGIA	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Musculoskeletal and connective tissue disorders SENSATION OF HEAVINESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders DIZZINESS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	37.5% 3/8 • Number of events 8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders DYSGEUSIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders HYPOSMIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders MEMORY IMPAIRMENT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders NEURALGIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders NEUROPATHY PERIPHERAL	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders PARAESTHESIA	33.3% 1/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders PERIPHERAL SENSORY NEUROPATHY	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders RESTLESS LEGS SYNDROME	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders SEDATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Nervous system disorders TREMOR	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders AGITATION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders ANXIETY	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders CONFUSIONAL STATE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders DEPRESSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders FLAT AFFECT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders INSOMNIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 2/4 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Psychiatric disorders SLEEP DISORDER	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders BLADDER PAIN	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders CHROMATURIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders DYSURIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders NOCTURIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders POLLAKIURIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders URINARY INCONTINENCE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders PRURITUS GENERALISED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Renal and urinary disorders URINARY RETENTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Reproductive system and breast disorders UTERINE HAEMORRHAGE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders ATELECTASIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders COUGH	33.3% 1/3 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders DYSPNOEA	33.3% 1/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	33.3% 1/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	66.7% 2/3 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	28.6% 2/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders EPISTAXIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders HAEMOPTYSIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders HICCUPS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders NASAL CONGESTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders PRODUCTIVE COUGH	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders RALES	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Respiratory, thoracic and mediastinal disorders RESPIRATORY TRACT CONGESTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders ALOPECIA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders COLD SWEAT	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders DRUG ERUPTION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders ERYTHEMA	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders HYPERHIDROSIS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders PETECHIAE	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	16.7% 1/6 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders PRURITUS	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders RASH	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 2/6 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 2/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders RASH GENERALISED	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	50.0% 1/2 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders SKIN EXFOLIATION	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders SKIN LESION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	14.3% 1/7 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	25.0% 1/4 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Skin and subcutaneous tissue disorders SKIN TIGHTNESS	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Vascular disorders HOT FLUSH	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	33.3% 1/3 • Number of events 1 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/8 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.
Vascular disorders HYPOTENSION	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/6 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/7 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/4 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	12.5% 1/8 • Number of events 2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/3 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.	0.00% 0/2 • Up to approximately 72 weeks (Up to approximately 6 weeks after last dose of study treatment) The population consisted of all participants who received at least one dose of MK-8776.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.
Publication restrictions are in place

Restriction type: OTHER